XyloCor Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
XyloCor Therapeutics, Inc. - overview
Established
2013
Location
Wayne, PA, US
Primary Industry
Biotechnology
About
Founded in 2013 and based in Pennsylvania, US, XyloCor Therapeutics, Inc. is a biopharmaceutical company that develops gene therapy for people with cardiovascular disease. Ronald Crystal and Todd Rosengart are the co-founders of the company. In January 2024, XyloCor Therapeutics, Inc.
raised USD 67. 5 million in series B funding led by new investor Jeito Capital, with participation from returning investors EQT, Fountain Healthcare Partners, and Lumira Ventures. XyloCor's lead gene therapy product, XC001, is for individuals who have an inadequate endogenous self-revascularization response to ischemia. The XC001 and its prototype formulations are capable of robustly enhancing the blood supply to ischemic tissues in animal models and in clinical testing.
The firm's secondary product, XC002, is for patients with cardiac tissue damage from heart attacks. The company will use the funding to support two Phase 2b clinical trials of XC001, one for refractory angina using a new non-surgical endocardial injection method, and another as an adjunctive treatment to coronary artery bypass graft surgery.
Current Investors
Sofinnova Investments, EQT Life Sciences, Fountain Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Cardiology, Pharmaceutical Research & Development
Website
www.xylocor.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.